Independent PatientView Survey

Corporate Reputation of Pharma 2024/5: Launches Tuesday 29 April

■ Two decades of experience
■ An extensive evidence base of patient-group views
■ 46 companies involved
■ Now in its 14^th year
■ Database of 40,000 patient groups worldwide
■ Survey conducted in 23 languages
■ Analyses based on geographic regions and therapy areas

■ Feedback from 2500+ patient groups in 2025; a record number

A record number of patient-group responses:

Respondent patient groups 2024/5:familiarity and partnerships with pharma

Specialities of patient-group respondents 2024/5

Country headquarters of respondent patient groups

Pharmaceutical companies included in PatientView’s Corporate Reputation of Pharma 2024/2025:

New companies for 2024/2025 included in bold*:

AbbVie • Amgen / including Horizon • Alnylam Pharmaceuticals • Angelini Pharma • Astellas Pharma • AstraZeneca / including Alexion • Bayer • Biogen • BioMarin • Boehringer Ingelheim • Bristol Myers Squibb • Chiesi / including Amyrt • Crinetics Pharmaceuticals • CSL Behring • Daiichi Sankyo • Eisai • Esteve Healthcare • Eli Lilly • Exelixis • Gilead Sciences / including Kite Pharma • GSK • Incyte • Ipsen • Johnson & Johnson Innovative Medicine (formerly Janssen) • Jazz Pharmaceuticals • LEO Pharma • Lundbeck • Merck KGaA/EMD Serono • Merck & Co/MSD • Novartis • Novo Nordisk • Otsuka • Pfizer • PTC Therapeutics • Recordati • Regeneron Pharmaceuticals • Roche/Genentech/Chugai • Sanofi • Sarepta Therapeutics • Servier • Sobi • Takeda • UCB • Vertex • Viatris • ViiV Healthcare

[Find out more on PatientView’s methodology for this survey]

**[Find out more about Corporate Reputation of Pharma from a Patient Perspective: Types of Data Analysed]**